# Chengdu Biocity

> Chengdu Biocity is a VC fund backing Medical, Pharmaceutical and Biotechnology. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 6
- Last investment: Jun 2023
- Lead investor: 0%
- Last updated: Aug 2026

Chengdu Biocity is an investment firm.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 5 | 83% |
| Pharmaceutical | 4 | 67% |
| Biotechnology | 3 | 50% |
| Health Care | 2 | 33% |
| Biopharma | 1 | 17% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 50% |
| Series B | 1 | 17% |
| Series C | 1 | 17% |
| Series E | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Joyo Pharma | Joyo Pharma focuses on the research and development of drugs for the treatment of tumors, autoimmunity, metabolism, and infectious diseases. | $14M | Series C | Jun 07, 2023 |  |
| TechnoDerma Medicines | TechnoDerma Medicines focuses on the research and development of innovative skin drugs for external use. |  | Series A | Jan 13, 2023 |  |
| Xilingyuan Pharmaceutical | Xilingyuan Pharmaceutical is a generic drug and innovative drug developer. | $12.6M | Series B | Nov 24, 2022 |  |
| Zenitar | Baoling Bio is an innovative drug research and development and industrialization service provider. The company's research and development pipeline covers the research and development of innovative drugs such as tumors (solid tumors and hematomas), autoimmune diseases, and cytokine storms caused by new coronavirus pneumonia. | $16.8M | Series A | Dec 08, 2021 |  |
| Feitong Bio | Feitong Bio platform discovers and develops innovative drugs using monoclonal antibody screening, molecular activity detection. | $15.7M | Series A | Dec 01, 2021 |  |
| Biostar Technologies | Beijing Biostar Technologies, Ltd. was incorporated in Haidian Park, Zhongguancun Science and Technology Park, Beijing, in July 2002. The national high-tech led by the team of Chinese scientists in the United States led by Dr. Tang Li and Dr. Qiu Rongguo. The company, focusing on biomedical development, technology and transfer of anti-tumor smallmolecule chemical drugs, and technical service consulting, pioneered the creation of new anti-cancer drugs for epothilone in China, and its technology is at the international advanced level. | $890M | Series E | Nov 26, 2020 |  |

6 of 6 investments shown.

## Co-investors
- Anxin Guosheng Microchip Fund — VC Fund, 1 deal together
- [CCB International](https://shizune.co/investors/profile/ccb-international) — VC Fund, 1 deal together
- Chengdu Hi-tech Investment Group — VC Fund, 1 deal together
- Chengdu Hi-tech Investment Group — VC Fund, 1 deal together
- [EFung Capital](https://shizune.co/investors/profile/efung-capital) — VC Fund, 1 deal together
- [Hongke Baishi](https://shizune.co/investors/profile/hongke-baishi) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Chengdu Biocity invest in?

Chengdu Biocity invests primarily in Medical, Pharmaceutical and Biotechnology startups, most often at Series A and Series B stage. Most of the 6 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Chengdu Biocity last invest?

The most recent investment recorded for Chengdu Biocity closed in Jun 2023. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co